164 related articles for article (PubMed ID: 17293689)
1. Aldosterone, mineralocorticoid receptors, and vascular inflammation.
Fiebeler A; Muller DN; Shagdarsuren E; Luft FC
Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):134-42. PubMed ID: 17293689
[TBL] [Abstract][Full Text] [Related]
2. Interactions of high salt intake and the response of the cardiovascular system to aldosterone.
Conlin PR
Cardiol Rev; 2005; 13(3):118-24. PubMed ID: 15831143
[TBL] [Abstract][Full Text] [Related]
3. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
Duprez DA
J Hypertens; 2006 Jun; 24(6):983-91. PubMed ID: 16685192
[TBL] [Abstract][Full Text] [Related]
4. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors.
Lemarié CA; Simeone SM; Nikonova A; Ebrahimian T; Deschênes ME; Coffman TM; Paradis P; Schiffrin EL
Circ Res; 2009 Oct; 105(9):852-9. PubMed ID: 19762686
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation.
Young MJ
Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):174-80. PubMed ID: 18277151
[TBL] [Abstract][Full Text] [Related]
6. New aspects of rapid aldosterone signaling.
Grossmann C; Gekle M
Mol Cell Endocrinol; 2009 Sep; 308(1-2):53-62. PubMed ID: 19549592
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone and end-organ damage.
Marney AM; Brown NJ
Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
[TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor activation in obesity hypertension.
Nagase M; Fujita T
Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
[TBL] [Abstract][Full Text] [Related]
9. Vascular actions of aldosterone.
Briet M; Schiffrin EL
J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
[TBL] [Abstract][Full Text] [Related]
10. Essential hypertension: is there a role for inflammatory mechanisms?
Androulakis ES; Tousoulis D; Papageorgiou N; Tsioufis C; Kallikazaros I; Stefanadis C
Cardiol Rev; 2009; 17(5):216-21. PubMed ID: 19690472
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular benefits of aldosterone receptor antagonists.
Williams GH
Climacteric; 2003 Oct; 6 Suppl 3():29-35. PubMed ID: 15018246
[TBL] [Abstract][Full Text] [Related]
12. Extrarenal effects of aldosterone.
Nguyen Dinh Cat A; Jaisser F
Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):147-56. PubMed ID: 22240440
[TBL] [Abstract][Full Text] [Related]
13. A quick glance at rapid aldosterone action.
Lösel R; Schultz A; Wehling M
Mol Cell Endocrinol; 2004 Mar; 217(1-2):137-41. PubMed ID: 15134812
[TBL] [Abstract][Full Text] [Related]
14. Rapid actions of aldosterone in vascular health and disease--friend or foe?
Skøtt O; Uhrenholt TR; Schjerning J; Hansen PB; Rasmussen LE; Jensen BL
Pharmacol Ther; 2006 Aug; 111(2):495-507. PubMed ID: 16413609
[TBL] [Abstract][Full Text] [Related]
15. [Profibrotic effects of aldosterone].
Van Den Meiracker AH; Huizenga AT; Boomsma F
Ned Tijdschr Geneeskd; 2004 Jul; 148(31):1532-6. PubMed ID: 15366722
[TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
17. [Aldosterone].
Miyamori I
Nihon Rinsho; 2004 Jan; 62(1):37-42. PubMed ID: 14737833
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone and inflammation.
Gilbert KC; Brown NJ
Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):199-204. PubMed ID: 20422780
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid resistance.
Geller DS
Clin Endocrinol (Oxf); 2005 May; 62(5):513-20. PubMed ID: 15853818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
